

TMSDRDSI: Drug Design MSc

TMSDRDSING01: MSc Drug Design

WIBRG001, WIBRG002, WIBRG003, WIBRG004, 5 + 6

View Online



1.

Wilhelm S. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. *Nature Reviews Drug Discovery*. 2006 Oct;5(10):835–44.

2.

Smith RA. Discovery of heterocyclic ureas as a new class of raf kinase inhibitors: identification of a second generation lead by a combinatorial chemistry approach. *Bioorganic & Medicinal Chemistry Letters*. 2001 Oct;11(20):2775–8.

3.

Kola I, Landis J. Opinion: Can the pharmaceutical industry reduce attrition rates? *Nature Reviews Drug Discovery*. 2004 Aug;3(8):711–6.

4.

Swinney DC, Anthony J. How were new medicines discovered? *Nature Reviews Drug Discovery*. 2011 Jun 24;10(7):507–19.

5.

Macarron R, Banks MN, Bojanic D, Burns DJ, Cirovic DA, Garyantes T, et al. Impact of high-throughput screening in biomedical research. *Nature Reviews Drug Discovery*. 2011 Mar;10(3):188–95.

6.

Selzer, P. M., Rohwer, A., Marhöfer, R. J. Applied bioinformatics: an introduction. Berlin: Springer; 2008.

7.

Xiong, Jin. Essential bioinformatics. New York: Cambridge University Press; 2006.

8.

Orengo, Christine Ann, Thornton, Janet M., Jones, David Tudor. Bioinformatics: genes, proteins and computers [Internet]. Oxford: BIOS; 2003. Available from: <http://www.vlebooks.com/vleweb/product/openreader?id=UCL&isbn=9780203427828>

9.

Zvelebil, Marketa J., Baum, Jeremy O. Understanding bioinformatics [Internet]. London: Garland Science; 2008. Available from: https://bibliu.com/app/#/view/books/9781136976964/pdf2htmlex/index.html#page_Cover

10.

Gu, Jenny, Bourne, Philip E. Structural bioinformatics. 2nd ed. Vol. Methods of biochemical analysis. Hoboken, N.J.: Wiley; 2008.

11.

Petsko, Gregory A., Ringe, Dagmar. Protein structure and function. Vol. Primers in biology. London: New Science; 2004.

12.

Nelson, David L., Cox, Michael M., Lehninger, Albert L. Lehninger principles of biochemistry. 5th ed. Basingstoke: W.H. Freeman; 2008.

13.

Chandra N. Computational systems approach for drug target discovery. *Expert Opinion on Drug Discovery*. 2009 Dec;4(12):1221–36.

14.

Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there? *Nature Reviews Drug Discovery*. 2006 Dec;5(12):993–6.

15.

Fitt R, Nodder E. Setting the threshold for industrial application: the UK diverges from Europe. *Journal of Intellectual Property Law & Practice*. 2010 Jun 4;5(8):560–5.

16.

Ikura M, Inouye M. NMR structure of the histidine kinase domain of the *E. coli* osmosensor EnvZ : Article : *Nature*. *Nature*. 1998 Nov 5;396(6706):88–92.

17.

Krohn KA, Link JM. Interpreting enzyme and receptor kinetics: keeping it simple, but not too simple. *Nuclear Medicine and Biology*. 2003 Nov;30(8):819–26.

18.

Jarnagin K. Receptor Binding in Drug Discovery. In: *eLS*.

19.

Jarnagin K. Receptor Binding in Drug Discovery. *Encyclopedia of Life Sciences*. Chichester: John Wiley & Sons, Ltd; 2001.

20.

Cornish-Bowden, Athel. *Fundamentals of enzyme kinetics*. 3rd ed. London: Portland; 2004.

21.

Copeland, Robert Allen. Evaluation of enzyme inhibitors in drug discovery: a guide for medicinal chemists and pharmacologists [Internet]. Vol. Methods of biochemical analysis. Hoboken, N.J.: J. Wiley; 2005. Available from: <https://onlinelibrary.wiley.com/doi/book/10.1002/9781118540398>

22.

Gibb, Alasdair J., Foreman, John C., Johansen, Torben. Textbook of receptor pharmacology. 3rd ed. Boca Raton, FL: CRC Press; 2011.

23.

Rang, H. P., Dale, M. Maureen. Pharmacology [Internet]. 9th ed. Edinburgh: Churchill Livingstone; 2019. Available from: <https://elsevierelibrary.co.uk/product/9780702074462>

24.

Colquhoun D. Binding, gating, affinity and efficacy: The interpretation of structure-activity relationships for agonists and of the effects of mutating receptors. British Journal of Pharmacology. 1998 Nov;125(5):923-47.

25.

Khawaja X, Dunlop J, Kowal D. Scintillation proximity assay in lead discovery. Expert Opinion on Drug Discovery. 2008 Nov;3(11):1267-80.

26.

Kenakin TP. Cellular assays as portals to seven-transmembrane receptor-based drug discovery. Nature Reviews Drug Discovery. 2009 Jul 17;8(8):617-26.

27.

Dunlop J. High-throughput electrophysiology: an emerging paradigm for ion-channel screening and physiology. Nature Reviews Drug Discovery. 2008 Apr;7(4):358-68.

28.

Hopkins AL, Groom CR. Opinion: The druggable genome. *Nature Reviews Drug Discovery*. 2002 Sep;1(9):727–30.

29.

Richard M. Durbin. A map of human genome variation from population-scale sequencing. *Nature*. 2010 Oct 28;467(7319):1061–73.

30.

Thomas, Gareth. *Fundamentals of medicinal chemistry*. 2003.

31.

Patrick, Graham L. *An introduction to medicinal chemistry*. 2017.

32.

Leach, Andrew R., Gillet, Valerie J. *An introduction to chemoinformatics*. 2003.

33.

Engel, Thomas, Gasteiger, J. *Chemoinformatics: a textbook*. 2003.

34.

Gasteiger, J. *Handbook of chemoinformatics: from data to knowledge* [Internet]. 2003. Available from: <https://onlinelibrary.wiley.com/doi/book/10.1002/9783527618279>

35.

Bissantz C, Kuhn B, Stahl M. A Medicinal Chemist's Guide to Molecular Interactions. *Journal of Medicinal Chemistry* [Internet]. 2010 Jul 22;53(14):5061–84. Available from: <https://contentstore.cla.co.uk/secure/link?id=fb92e363-cb0b-f011-90cc-c5989c4ef87d>

36.

Matter H. Selecting Optimally Diverse Compounds from Structure Databases: A Validation Study of Two-Dimensional and Three-Dimensional Molecular Descriptors. *Journal of Medicinal Chemistry* [Internet]. 1997 Apr;40(8):1219–29. Available from: <https://contentstore.cla.co.uk/secure/link?id=c491b572-220b-f011-90cc-c5989c4ef87d>

37.

Willett P, Barnard JM, Downs GM. Chemical Similarity Searching. *Journal of Chemical Information and Modeling* [Internet]. 1998 Nov 23;38(6):983–96. Available from: <https://contentstore.cla.co.uk/secure/link?id=e44202ff-cd0b-f011-90cc-c5989c4ef87d>

38.

Welsch ME, Snyder SA, Stockwell BR. Privileged scaffolds for library design and drug discovery. *Current Opinion in Chemical Biology*. 2010 Jun;14(3):347–61.

39.

Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Advanced Drug Delivery Reviews*. 1997 Jan;23(1–3):3–25.

40.

Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular Properties That Influence the Oral Bioavailability of Drug Candidates. *Journal of Medicinal Chemistry* [Internet]. 2002 Jun;45(12):2615–23. Available from: <https://contentstore.cla.co.uk/secure/link?id=de13eed7-c90b-f011-90cc-c5989c4ef87d>

41.

Blake JF. Identification and Evaluation of Molecular Properties Related to Preclinical Optimization and Clinical Fate. *Medicinal Chemistry*. 2005 Nov 1;1(6):649–55.

42.

Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. *Nature Reviews Immunology*. 2010 May;10(5):345–52.

43.

Bradbury ARM, Sidhu S, Dübel S, McCafferty J. Beyond natural antibodies: the power of in vitro display technologies. *Nature Biotechnology*. 2011 Mar;29(3):245–54.

44.

Nagorsen D, Baeuerle PA. Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. *Experimental Cell Research*. 2011 May;317(9):1255–60.

45.

Pillay V, Gan HK, Scott AM. Antibodies in oncology. *New Biotechnology*. 2011 Sep;28(5):518–29.

46.

Schrama D, Reisfeld RA, Becker JC. Antibody targeted drugs as cancer therapeutics. *Nature Reviews Drug Discovery*. 2006 Jan 20;5(2):147–59.

47.

Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. *Nature Reviews Immunology*. 2010 May;10(5):317–27.

48.

Ducry L, Stump B. Antibody–drug conjugates: Linking cytotoxic payloads to monoclonal antibodies. *Bioconjugate chemistry*. 2010 Jan 20;21(1):5–13.

49.

Alley SC, Okeley NM, Senter PD. Antibody–drug conjugates: targeted drug delivery for cancer. *Current Opinion in Chemical Biology*. 2010 Aug;14(4):529–37.

50.

Webb S. Pharma interest surges in antibody drug conjugates. *Nature Biotechnology*. 2011 Apr;29(4):297–8.

51.

Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. *Nature Biotechnology*. 2005 Sep;23(9):1126–36.

52.

Jinek M, Doudna JA. A three-dimensional view of the molecular machinery of RNA interference. *Nature*. 2009 Jan 22;457(7228):405–12.

53.

Castanotto D, Rossi JJ. The promises and pitfalls of RNA-interference-based therapeutics. *Nature*. 2009 Jan 22;457(7228):426–33.

54.

Grimm D. Small silencing RNAs: State-of-the-art. *Advanced Drug Delivery Reviews*. 2009 Jul;61(9):672–703.

55.

Vaishnaw AK, Gollob J, Gamba-Vitalo C, Hutabarat R, Sah D, Meyers R, et al. A status report on RNAi therapeutics. *Silence*. 2010;1(1).

56.

Shen J, Samul R, Silva RL, Akiyama H, Liu H, Saishin Y, et al. Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. *Gene Therapy*. 2005 Sep 29;13(3):225–34.

57.

Kalluri R, Kanasaki K. RNA interference: Generic block on angiogenesis. *Nature*. 2008 Apr 3;452(7187):543–5.

58.

Human embryonic stem cells: Derivation, culture, and differentiation: A review.

59.

Stadtfield M, Hochedlinger K. Induced pluripotency: history, mechanisms, and applications. *Genes & Development*. 2010 Oct 15;24(20):2239–63.

60.

Watt FM, Driskell RR. The therapeutic potential of stem cells. *Philosophical Transactions of the Royal Society B: Biological Sciences*. 2010 Jan 12;365(1537):155–63.

61.

Brignier AC, Gewirtz AM. Embryonic and adult stem cell therapy. *Journal of Allergy and Clinical Immunology*. 2010 Feb;125(2):S336–44.

62.

Lledo PM, Merkle FT, Alvarez-Buylla A. Origin and function of olfactory bulb interneuron diversity. *Trends in Neurosciences*. 2008 Aug;31(8):392–400.

63.

Murray CW. Fragment-Based Drug Discovery Applied to Hsp90. Discovery of Two Lead Series with High Ligand Efficiency. *Journal of Medicinal Chemistry*. 2010 Aug 26;53(16):5942–55.

64.

Hopkins AL, Groom CR, Alex A. Ligand efficiency: a useful metric for lead selection. *Drug Discovery Today*. 2004 May;9(10):430–1.

65.

Congreve M, Chessari G, Tisi D, Woodhead AJ. Recent Developments in Fragment-Based Drug Discovery. *Journal of Medicinal Chemistry* [Internet]. 2008 Jul;51(13):3661–80. Available from: <https://contentstore.cla.co.uk/secure/link?id=0bbaf30c-e20b-f011-90cc-c5989c4ef87d>

66.

Murray CW, Rees DC. The rise of fragment-based drug discovery. *Nature Chemistry*. 2009 Jun;1(3):187–92.

67.

Baurin N, Aboul-Ela F, Barril X, Davis B, Drysdale M, Dymock B, et al. Design and Characterization of Libraries of Molecular Fragments for Use in NMR Screening against Protein Targets. *Journal of Chemical Information and Modeling* [Internet]. 2004 Nov 22;44(6):2157–66. Available from: <https://contentstore.cla.co.uk/secure/link?id=e3feb169-e40b-f011-90cc-c5989c4ef87d>

68.

Woodhead AJ. Discovery of (2,4-Dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a Novel Inhibitor of the Molecular Chaperone Hsp90 by Fragment Based Drug Design. *Journal of Medicinal Chemistry* [Internet]. 2010 Aug 26;53(16):5956–69. Available from: <https://contentstore.cla.co.uk/secure/link?id=2cf7cd66-e30b-f011-90cc-c5989c4ef87d>

69.

DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. *Journal of Health Economics*. 2003 Mar;22(2):151–85.